Skip to main content
Testing version — LOERadar is in active testing. Features and data may change.
LOERadar
LOE
Radar
Hub
News
Changes
Search
Log in
Get Started
ONSOLIS (FENTANYL CITRATE) | LOERadar
Viewing data from:
Latest
2026-07-01
2026-06-01
2026-05-01
2026-04-01
2026-03-28
2026-02-17
2026-02-10
2025-12-14
2025-02-26
2025-01-25
2024-11-08
2023-07-23
2023-06-15
2023-05-13
2023-01-26
2022-11-22
2022-10-28
2022-09-29
2022-07-09
2022-06-29
2022-04-08
2022-03-09
2021-12-28
2021-05-05
2021-03-12
2020-12-22
2020-11-12
2019-12-14
2019-09-15
ONSOLIS
NDA
Get alerts
FENTANYL CITRATE | N022266 | ADALVO LTD
5 strengths
1 unique patent
0 unique exclusivities
Patents
SEC Intel
Revenue
PTAB
Reexams
Litigation
Petitions
Trials
DMF
Approvals
Label
Products
Patent Timeline
1 unique patent by expiration date
All strengths
EQ 0.2MG BASE
EQ 0.4MG BASE
EQ 0.6MG BASE
EQ 0.8MG BASE
EQ 1.2MG BASE
Active (1)
Today
2027
Today
9597288
Jul. 23, 2027
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
No ANDA patent litigation cases (NOS 835) matched from PACER
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (5)
Sort:
Name
↑
Applicant
Strength
Approval
#001 — EQ 0.2MG BASE
1 patent
0 exclusivities
▴
FILM;BUCCAL | Approved: Jul 16, 2009
Patents (1)
Patent #
Expiration
PED
Drug Substance
Drug Product
Use Code
Delist
9597288
Jul 23, 2027
—
—
Yes
U-767
MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER
—
#002 — EQ 0.4MG BASE
1 patent
0 exclusivities
▾
FILM;BUCCAL | Approved: Jul 16, 2009
#003 — EQ 0.6MG BASE
1 patent
0 exclusivities
▾
FILM;BUCCAL | Approved: Jul 16, 2009
#004 — EQ 0.8MG BASE
1 patent
0 exclusivities
▾
FILM;BUCCAL | Approved: Jul 16, 2009
#005 — EQ 1.2MG BASE
1 patent
0 exclusivities
▾
FILM;BUCCAL | Approved: Jul 16, 2009